Med BioGene Valuation
| MBGNF Stock | USD 0.01 0.00 0.00% |
Med BioGene seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Med BioGene from analyzing the firm fundamentals such as Shares Outstanding of 17.26 M, price to earning of (3.33) X, and Return On Asset of -2.48 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Med BioGene's price fluctuation is unstable at this time. Calculation of the real value of Med BioGene is based on 3 months time horizon. Increasing Med BioGene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Med pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Med BioGene. Since Med BioGene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Med Pink Sheet. However, Med BioGene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0059 | Real 0.004956 | Hype 0.0059 | Naive 0.0059 |
The real value of Med Pink Sheet, also known as its intrinsic value, is the underlying worth of Med BioGene Company, which is reflected in its stock price. It is based on Med BioGene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Med BioGene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Med BioGene helps investors to forecast how Med pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Med BioGene more accurately as focusing exclusively on Med BioGene's fundamentals will not take into account other important factors: Med BioGene Total Value Analysis
Med BioGene is now estimated to have takeover price of 251.67 K with market capitalization of 1.83 M, debt of 0, and cash on hands of 38.6 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Med BioGene fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
251.67 K | 1.83 M | 0 | 38.6 K |
Med BioGene Asset Utilization
One of the ways to look at asset utilization of Med is to check how much profit was generated for every dollar of assets it reports. Med BioGene secures a negative usage of assets of -2.48 %, losing $0.0248 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Med BioGene shows how discouraging it operates for each dollar spent on its assets.Med BioGene Ownership Allocation
Med BioGene maintains a total of 17.26 Million outstanding shares. Med BioGene holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Med BioGene Profitability Analysis
Net Loss for the year was (59.96 K) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Med BioGene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Med BioGene and how it compares across the competition.
About Med BioGene Valuation
The pink sheet valuation mechanism determines Med BioGene's current worth on a weekly basis. Our valuation model uses a comparative analysis of Med BioGene. We calculate exposure to Med BioGene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Med BioGene's related companies.Previously, it was engaged in the life science business with a focus on the development and commercialization of genomic-based clinical tests for non-small-cell lung cancer. Med BioGene Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada. Med Biogene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Med BioGene's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Med BioGene's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Med BioGene's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Med BioGene's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Med BioGene's revenue streams: Identify Med BioGene's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Med BioGene's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Med BioGene's growth potential: Evaluate Med BioGene's management, business model, and growth potential.
- Determine Med BioGene's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Med BioGene's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Med BioGene Growth Indicators
Investing in growth stocks can be very risky. If the company such as Med BioGene does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 15.3 M | |
| Retained Earnings | -14.7 M |
Complementary Tools for Med Pink Sheet analysis
When running Med BioGene's price analysis, check to measure Med BioGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Med BioGene is operating at the current time. Most of Med BioGene's value examination focuses on studying past and present price action to predict the probability of Med BioGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Med BioGene's price. Additionally, you may evaluate how the addition of Med BioGene to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |